Prof Daniel Petrylak talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about a study looking at the novel agent enfortumab vedotin targeting Nectin-4 as treatment for patients with advanced urothelial cancer.
He explains that Nectin-4 is a protein that helps cancer cells stick together and it is expressed in 97% urothelial cancers.
Prof Petrylak reports that overall 44% of patients who received the targeting agent responded to treatment and also that a response was seen across the different subgroups.
Watch the press conference here.
Read the news story here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.